SEC SCHEDULE 13G

Company

Aclaris Therapeutics, Inc.

Filed

February 4, 2022

Accession Number

0001678858-22-000098

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →